Dr Eugenia M Miller, MD | |
1 Mercado Street, Suite 130, Durango, CO 81301-7306 | |
(970) 247-1120 | |
(970) 247-3664 |
Full Name | Dr Eugenia M Miller |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 1 Mercado Street, Durango, Colorado |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1114992450 | NPI | - | NPPES |
01232941 | Medicaid | CO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0000X | Internal Medicine - Cardiovascular Disease | 23294 (Colorado) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Eugenia M Miller, MD 181 East 56th Avenue, Suite 100, Denver, CO 80216-1756 Ph: (303) 295-8737 | Dr Eugenia M Miller, MD 1 Mercado Street, Suite 130, Durango, CO 81301-7306 Ph: (970) 247-1120 |
News Archive
Cancer survivors joined representatives from ProCure Treatment Centers, Inc., Princeton Radiation Oncology, and CentraState Healthcare System to break ground on the ProCure Proton Therapy Center in Somerset - the first proton therapy center to be built in the state, located 40 miles from downtown Manhattan.
Bacteria, transformed into dormant spores, can survive millions of years in extreme environments, threatening human life in the form of food poisoning and the biological weapon anthrax. But understanding how bacteria adapt to hostile environments has largely remained a mystery-until now.
In 2000, researchers at the UCLA Center for Sleep Research published findings showing that people suffering from narcolepsy, a disorder characterized by uncontrollable periods of deep sleep, had 90 percent fewer neurons containing the neuropeptide hypocretin in their brains than healthy people.
Lexicon Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted its request for Orphan Drug designation for telotristat etiprate (LX1032) for the treatment of carcinoid syndrome.
Taro Pharmaceutical Industries Ltd. reported today that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for cetirizine hydrochloride oral solution, 1 mg / 1 mL ("Cetirizine Oral Solution").
› Verified 3 days ago
Richard A Brown, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1010 Three Springs Blvd, Ste 110, Durango, CO 81301 Phone: 970-764-2750 Fax: 970-764-2778 | |
Dr. Richard L Converse Jr., MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Mercado St Ste 130, Durango, CO 81301 Phone: 970-247-1120 Fax: 970-247-1128 | |
Mr. Stuart Saslow, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1305 Escalante Dr Suite 204, Durango, CO 81303 Phone: 970-385-4022 Fax: 970-385-4337 | |
Dr. Erin Gray Clarkinson, DO Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1199 Main Ave Ste 206, Durango, CO 81301 Phone: 970-422-8147 | |
Lyla Saeed, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1010 Three Springs Blvd Ste 270, Durango, CO 81301 Phone: 970-764-3800 Fax: 970-764-3840 | |
Sarah E. Brown, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1010 Three Springs Blvd, Durango, CO 81301 Phone: 970-764-3352 Fax: 970-764-3375 |